Comparing Dapagliflozin vs Januvia
| Dapagliflozin | Januvia (sitagliptin) |
|
|---|
| Dapagliflozin | Januvia (sitagliptin) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Heart Failure, Chronic Kidney Disease, Type 2 Diabetes. Dapagliflozin may also be used for purposes not listed in this medication guide. |
Prescription only
Januvia is a DPP-4 inhibitor that is used in addition to other medications for the treatment of type 2 diabetes. Rarely, it may cause joint pain, skin reactions, pancreatitis, or an allergic... View more |
Related suggestions Type 2 Diabetes
Popular comparisons
|
|||||||
| More about Dapagliflozin | More about Januvia (sitagliptin) | ||||||||
| Ratings & Reviews | |||||||||
|
Dapagliflozin has an average rating of 4.7 out of 10 from a total of 195 ratings on Drugs.com. 28% of reviewers reported a positive effect, while 46% reported a negative effect. |
Januvia has an average rating of 4.5 out of 10 from a total of 139 ratings on Drugs.com. 29% of reviewers reported a positive effect, while 53% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Dapagliflozin side effects |
View all Januvia side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
Lower cost generic |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Dapagliflozin prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
| Farxiga | Other sitagliptin brands include: Brynovin, Zituvio | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
12.9 hours |
12.4 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 372 drugs are known to interact with Dapagliflozin:
|
A total of 296 drugs are known to interact with Januvia:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
January 08, 2014 |
October 16, 2006 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Mounjaro
Mounjaro is used to treat type 2 diabetes in adults. It is a subcutaneous injection that can be ...
Jardiance
Jardiance (empagliflozin) is used to treat type 2 diabetes, chronic kidney disease and reduce the ...
Farxiga
Farxiga (dapagliflozin) is an oral prescription medication that may be given to certain adults with ...
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Entresto
Entresto is an oral combination heart medication that contains two blood pressure-lowering ...
Trulicity
Trulicity is an injectable diabetes medicine that is used together with diet and exercise to ...
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.